Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid

• Egile Nagusiak: Lin Lin (Egilea), Fei Hua (Egilea), Cristian Salinas (Egilea), Carissa Young (Egilea), Thierry Bussiere (Egilea), Joshua F. Apgar (Egilea), John M. Burke (Egilea), Kumar Kandadi Muralidharan (Egilea), Rajasimhan Rajagovindan (Egilea), Ivan Nestorov (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD. Aducanumab is a human, immunoglobulin gamma 1 monoclonal ant...